Dr. Agarwal's Health Care Ltd. (IN:AGARWALEYE)
:AGARWALEYE
Top Page
Dr. Agarwal's Health Care Ltd.
(AGARWALEYE)
Select Model
Select Model
Rating:73Outperform
Price Target:
₹485.00
▼(-3.00% Downside)
Action:ReiteratedDate:10/23/25
Dr. Agarwal's Health Care Ltd. demonstrates strong financial performance with significant revenue and profit growth, which is the most significant factor in the overall score. Technical analysis indicates positive momentum, though caution is advised due to overbought signals. The lack of valuation metrics introduces some uncertainty, slightly impacting the overall score.
Positive Factors
Revenue and margin improvement
Sustained revenue growth with rising EBIT/EBITDA margins signals durable demand and better operational efficiency across clinics. Over 2–6 months this supports reinvestment in capacity, enhances cash flow conversion and underpins long-term profitability as volumes scale.
Negative Factors
Moderately high leverage
A moderately high debt-to-equity ratio raises structural financing risk: higher interest expense can pressure net margins and reduce flexibility for opportunistic investments. Over 2–6 months this increases sensitivity to cash flow swings and constrains balance sheet optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and margin improvement
Sustained revenue growth with rising EBIT/EBITDA margins signals durable demand and better operational efficiency across clinics. Over 2–6 months this supports reinvestment in capacity, enhances cash flow conversion and underpins long-term profitability as volumes scale.
Read all positive factors
Dr. Agarwal's Health Care Ltd. (AGARWALEYE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹134.74B
Dividend YieldN/A
Average Volume (3M)13.83K
Price to Earnings (P/E)118.8
Beta (1Y)0.58
Revenue GrowthN/A
EPS GrowthN/A
CountryIN
Employees4,214
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.10
Shares Outstanding316,807,500
10 Day Avg. Volume7,500
30 Day Avg. Volume13,832
Financial Highlights & Ratios
PEG Ratio43.43
Price to Book (P/B)7.19
Price to Sales (P/S)7.85
P/FCF Ratio589.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.6
Revenue Forecast (FY)₹24.77B
Dr. Agarwal's Health Care Ltd. Business Overview & Revenue Model
Company Description
Dr. Agarwal's Health Care Limited operates eye hospitals in India and internationally. It offers cataract surgeries, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery, and glued intraocular lens treatments; and...
How the Company Makes Money
The company primarily makes money by delivering clinical ophthalmology services through its hospital/clinic network. Key revenue streams include: (1) Surgical and procedure revenue: fees from ophthalmic surgeries and interventional procedures (e.g...
Dr. Agarwal's Health Care Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.77B | 17.11B | 13.32B | 10.16B | 6.95B | 4.71B |
| Gross Profit | 8.87B | 9.91B | 3.85B | 2.96B | 1.91B | 2.87B |
| EBITDA | 5.23B | 4.99B | 4.50B | 2.84B | 1.96B | 428.70M |
| Net Income | 1.15B | 834.60M | 1.02B | 940.97M | 376.94M | -554.78M |
Balance Sheet | ||||||
| Total Assets | 37.86B | 36.72B | 27.83B | 18.25B | 10.26B | 7.87B |
| Cash, Cash Equivalents and Short-Term Investments | 3.97B | 5.22B | 5.87B | 1.61B | 996.21M | 552.12M |
| Total Debt | 9.83B | 9.61B | 9.68B | 8.57B | 6.19B | 4.69B |
| Total Liabilities | 17.67B | 17.45B | 13.89B | 11.66B | 7.92B | 5.88B |
| Stockholders Equity | 19.31B | 18.67B | 13.48B | 6.30B | 2.12B | 1.84B |
Cash Flow | ||||||
| Free Cash Flow | 495.00M | 227.90M | 1.14B | 753.05M | 937.40M | -273.94M |
| Operating Cash Flow | 2.62B | 3.31B | 3.46B | 2.33B | 1.64B | 991.59M |
| Investing Cash Flow | -1.36B | -7.54B | -9.14B | -5.09B | -1.55B | -365.69M |
| Financing Cash Flow | -1.32B | 4.14B | 5.53B | 3.03B | 354.33M | -371.07M |
Dr. Agarwal's Health Care Ltd. Technical Analysis
Positive
500.00
Price Trends
502.56
Positive
471.60
Positive
Market Momentum
-0.68
Positive
51.39
Neutral
47.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AGARWALEYE, the sentiment is Positive. The current price of 500 is below the 20-day moving average (MA) of 508.88, below the 50-day MA of 502.56, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -0.68 indicates Positive momentum. The RSI at 51.39 is Neutral, neither overbought nor oversold. The STOCH value of 47.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:AGARWALEYE.
Dr. Agarwal's Health Care Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹134.74B | 118.77 | ― | ― | ― | ― | |
71 Outperform | ₹79.15B | 18.03 | ― | 0.44% | 14.80% | 1.35% | |
67 Neutral | ₹82.55B | -247.47 | ― | ― | 17.58% | -38.20% | |
67 Neutral | ₹79.91B | 53.67 | ― | 0.14% | 18.40% | 7.30% | |
66 Neutral | ₹129.09B | 46.21 | ― | 0.22% | 9.91% | 9.57% | |
61 Neutral | ₹94.71B | 60.35 | ― | 0.21% | 15.41% | 5.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:AGARWALEYE
Dr. Agarwal's Health Care Ltd.
434.90
19.90
4.80%
IN:HCG
HealthCare Global Enterprises Ltd.
545.15
22.83
4.37%
IN:JLHL
Jupiter Life Line Hospitals Ltd.
1,232.15
-218.57
-15.07%
IN:MARKSANS
Marksans Pharma Limited
175.05
-29.78
-14.54%
IN:METROPOLIS
Metropolis Healthcare Ltd.
457.60
63.58
16.14%
IN:RAINBOW
Rainbow Childrens Medicare Limited
1,254.50
-276.70
-18.07%
Dr. Agarwal's Health Care Ltd. Corporate Events
Dr. Agarwal’s Health Care Grants 4.44 Lakh ESOPs Under 2022 Scheme
Feb 3, 2026
Dr. Agarwal’s Health Care Limited has granted 444,500 stock options under its Employees Stock Option Scheme 2022 to eligible employees of the company and its subsidiaries, following approval by the Nomination and Remuneration Committee at it...
Dr. Agarwal’s Health Care Gets Clean Monitoring Report on IPO Proceeds Utilisation
Feb 3, 2026
Dr. Agarwal’s Health Care Limited has disclosed that the independent Monitoring Agency, ICRA Limited, has confirmed there is no deviation in the company’s use of proceeds from its Initial Public Offer for the quarter ended December 31,...
Dr. Agarwal’s Health Care Sets Board Meet and Analyst Call for Q3 FY26 Results
Jan 28, 2026
Dr. Agarwal’s Health Care Limited has scheduled a board meeting on February 3, 2026, to consider and approve its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and has maintai...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.